GlassScriptPhysician profile
Kinzi Shewmake
NPI 1568473809
$5,726.48
in general payments reported to CMS, 2019-2025
35 companies · $1,471 in 2025
The $1,471 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $60.30 · 2021: $142 · 2022: $411 · 2023: $1,451 · 2024: $1,755 · 2025: $1,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,676.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $665.06 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $548.04 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $522.57 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $486.77 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $433.03 | 2019-2025 | |
| Lilly USA, LLC | $416.42 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $349.09 | 2023-2025 | Vraylar |
| Xeris Pharmaceuticals, INC. | $348.58 | 2021-2024 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $306.67 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $236.98 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Freedom Lite |
| Shield Therapeutics INC | $194.39 | 2023-2025 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $173.53 | 2021-2025 | |
| Horizon Therapeutics Plc | $163.23 | 2022-2023 | Krystexxa |
| Exact Sciences Corporation | $85.85 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $78.73 | 2024 | Veozah |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kinzi Shewmake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.